A major strategic shift prioritizes the neoadjuvant BOT/BAL program for high-risk MSS colon cancer, backed by robust phase II data and up to $340 million in financing. The ROBBIN phase III trial targets a large, underserved market, with FDA-aligned design and strong early clinical results.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.